Skip to main content
SpringerLink
Log in

Biomarkers in Neoadjuvant Trials

  • Chapter
  • First Online:
Hormone Receptors in Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 147))

  • 912 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rossouw E, Anderson GL, Prentice RL, et al., for Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative. JAMA 2002;288:321–333.

    Article  PubMed  CAS  Google Scholar 

  2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003;289:3243–3253.

    Article  PubMed  CAS  Google Scholar 

  3. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2002;362;419–427.

    Google Scholar 

  4. Abrial C, Mouret-Reynier MA, Cure H, et al. Neoadjuvant endocrine therapy in breast cancer. The Breast 2006;15:9–19.

    Article  PubMed  CAS  Google Scholar 

  5. Goldhirsch A, Wood WC, Gelber RD, et al, 10th St. Gallen conference. progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133–1144.

    Article  PubMed  CAS  Google Scholar 

  6. Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002;13:293–298.

    Article  PubMed  CAS  Google Scholar 

  7. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86:295–299.

    Article  PubMed  CAS  Google Scholar 

  8. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002;38(17):2214–2221.

    Article  PubMed  CAS  Google Scholar 

  9. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205–213

    Article  PubMed  CAS  Google Scholar 

  10. Jones LW, Haykowsky M, Pituskin EN, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancer. The Oncologist 2007;12:11.

    Article  Google Scholar 

  11. Buzdar A. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer—updated efficacy results based on a median follow-up of 47 months. San Antonio Breast Cancer Symposium 2002; abstr. 13.

    Google Scholar 

  12. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–947.

    Article  PubMed  Google Scholar 

  13. Coller JK, Krebsfaenger N, Klein K, et al. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br J Clin Pharmacol 2004;57:105–111.

    Article  PubMed  CAS  Google Scholar 

  14. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687–1717.

    Article  Google Scholar 

  15. Johnson MD, Zuo H, Lee KH, et al. Pharmacologic characterization of 4-hydroxy-N-desmethyl tamoxifen, a nover active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151–159.

    Article  PubMed  CAS  Google Scholar 

  16. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol 1991;39:783–90.

    Article  CAS  Google Scholar 

  17. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86:295–299.

    Article  PubMed  CAS  Google Scholar 

  18. Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomized trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996;7:471–9.

    PubMed  CAS  Google Scholar 

  19. Tominaga T, Adachi I, Sasaki Y, et al. Double-blind randomized trial comparing the nonsteroidal aromotase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol 2003;14:62–1470.

    Article  PubMed  CAS  Google Scholar 

  20. Silva E, Gatalica Z, Snyder C, et al. Hereditary breast cancer: Part II. Management of hereditary breast cancer: implications of molecular genetics and pathology. Breast J 2007. [Epub ahead of print]

    Google Scholar 

  21. Fitzgibbons P. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966.

    PubMed  CAS  Google Scholar 

  22. Bast R, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2000;19:1865.

    Google Scholar 

  23. Gokhale S, Rosen D, Sneige N, et al, Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 2007;15(4):451–455.

    Article  PubMed  CAS  Google Scholar 

  24. Green S, Walter P, Greene G, et al. Cloning of the human estrogen receptor cDNA. J Steroid Biochem 1986;24:77–83.

    Article  PubMed  CAS  Google Scholar 

  25. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434–2439.

    PubMed  CAS  Google Scholar 

  26. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86:295–299.

    Article  PubMed  CAS  Google Scholar 

  27. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25(36):5815–5824.

    Article  PubMed  CAS  Google Scholar 

  28. Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of estrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002;38:380-6.2000;92:179–181.

    Google Scholar 

  29. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Human Pathol 2001;32:113–118.

    Article  CAS  Google Scholar 

  30. Vinayagam R, Sibson DR, Holcombe C, et al. Association of estrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study. BMC Cancer 2007;18(7):131.

    Article  Google Scholar 

  31. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor ß (ERß) level but not its ERßcx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769–5776.

    Article  PubMed  CAS  Google Scholar 

  32. Jensen EV, Cheng G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001;98: 15197–15202.

    Google Scholar 

  33. Miller WR, Anderson TJ, Dixon JM, et al. Estrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer 2006;94(9):1333–8.

    Article  PubMed  CAS  Google Scholar 

  34. Knight W, Osborne C, McGuire W. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 1980;9:361.

    Article  PubMed  Google Scholar 

  35. Bezwoda W, Esser J, Dansey R, et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 1991;68:867.

    Article  PubMed  CAS  Google Scholar 

  36. Pertschuk L, Feldman J, Eisenberg K, et al. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Cancer 1988;62:342.

    Article  PubMed  CAS  Google Scholar 

  37. Leo JC, Lin VC. The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner. Int J Cancer 2008;122(1):230–243.

    Article  PubMed  CAS  Google Scholar 

  38. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523–6531.

    PubMed  CAS  Google Scholar 

  39. Tao Y, Klause A, Vickers A, et al. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Ster Biochem Mol Biol 2005;95:91–95.

    Article  CAS  Google Scholar 

  40. Dowsett M, Smith IE, Ebbs SR, et al., IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99(2):167–170.

    Article  PubMed  CAS  Google Scholar 

  41. Akashi-Tanaka S, Omatsu M, Shimizu C, et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast 2007;16(5):482–488.

    Article  PubMed  Google Scholar 

  42. Pierce JH, Arnstein P, DiMarco E, et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991;6:1189–1194.

    PubMed  CAS  Google Scholar 

  43. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

    Article  PubMed  CAS  Google Scholar 

  44. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB1- and/or ERB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  45. Preece PE, Wood RA, Mackie CR, et al. Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study. BMJ 1982;284:869–870.

    Article  PubMed  CAS  Google Scholar 

  46. Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: a cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991;78:591–594.

    Article  PubMed  CAS  Google Scholar 

  47. Van Dalsen AD, De Vries J. Treatment of breast cancer in elderly patients. J Surg Oncol 1995;60:80–82.

    Article  PubMed  Google Scholar 

  48. Tan SM, Cheung KL, Willsher PC, et al. Locally advanced primary breast cancer: medium-term results of a randomized trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001;37:2331–2338.

    Article  PubMed  CAS  Google Scholar 

  49. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs. surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207–214.

    PubMed  CAS  Google Scholar 

  50. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14(3):414–420.

    Article  PubMed  CAS  Google Scholar 

  51. Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39(3):309–316.

    Article  PubMed  CAS  Google Scholar 

  52. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191–199.

    Article  PubMed  CAS  Google Scholar 

  53. Paepke S, Tulusan A, Kiesel L, et al. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc ASCO 2003 (abstr. 321).

    Google Scholar 

  54. Renshaw L, Murray J, Young O, et al. Is there an optimal duration of neoadjuvant letrozole therapy? San Antonio 2004 (abstr. 405).

    Google Scholar 

  55. Miller WR, White S, Dixon JM, et al. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer. 2006;Apr 10;94(7):1051–1056.

    Google Scholar 

  56. Eiermann W, Paepke S, Appfelstaedt L, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12(11):1505–1506.

    Article  Google Scholar 

  57. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB1- and/or ERB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  58. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer; results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–2606.

    PubMed  CAS  Google Scholar 

  59. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101–2109.

    Article  PubMed  CAS  Google Scholar 

  60. Miller WR, Dixon JM, Cameron DA, et al. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001;79:103–107.

    Article  PubMed  CAS  Google Scholar 

  61. Miller WR, Dixon JM, Macfarlane L, et al. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003;39(4):462–468.

    Article  PubMed  CAS  Google Scholar 

  62. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB1- and/or ERB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  63. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007;105:33–43.

    Article  PubMed  CAS  Google Scholar 

  64. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blinded, single-center study. Clin Cancer Res 2000;6:2229–2235.

    PubMed  CAS  Google Scholar 

  65. Dixon JM, jackson J, Hills M, et al. Anatrozole demonstrates clinical and biological effectiveness in erbB2 ER positive breast cancers. San Antonio 2002 (abstr. 263).

    Google Scholar 

  66. Milla-Santos A, Milla I, Rallo L, et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts). Proc ASCO 2002;21 (abstr. 156).

    Google Scholar 

  67. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–3757.

    PubMed  CAS  Google Scholar 

  68. Nabholtz JM, Buzdar A, Pollak M, et al. Anatrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.

    PubMed  CAS  Google Scholar 

  69. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–2258.

    Article  PubMed  CAS  Google Scholar 

  70. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamixifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86:295–299.

    Article  PubMed  CAS  Google Scholar 

  71. Smith I, Dowsett M. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. San Antonio 2003 (abstr. 1).

    Google Scholar 

  72. Cataliotti L, Buzdar A, Noguchi S, et al. Efficacy of preoperative arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. Eur J Cancer 2004;2:46.

    Google Scholar 

  73. Dirix L, Piccart M, Lohrisch C, et al. Efficacy of and tolerance to exemestane versus tamoxifen in 1st line hormone therapy of postmenopausal metastatic breast cancer patients: a European Organization for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 200120:29a.

    Google Scholar 

  74. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391–1398.

    Article  PubMed  CAS  Google Scholar 

  75. Dixon JM, Anderson T, Miller WR. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer. Proc ASCO 2001 (abstr. 1908)

    Google Scholar 

  76. Wolf C, Hackl W, Kuemper S, et al. Exemestane combined with epirubicin, Q1wX, as preoperative chemoendocrine treatment for patients with primary breast cancer: a phase I study. Proc ASCO 2001 (abstr. 1819).

    Google Scholar 

  77. Lichtenegger W, Hackl W, Huettner C, et al. Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer. Proc ASCO 2001 (anstr. 1832).

    Google Scholar 

  78. Gil M, Barnadas A, Cirera L, et al. Exemestane as neoadjuvant treatment in patients >65 years with T>3 cm; preliminary results of a multicenter Spanish phase II trial. San Antonio 2002 (abstr. 272).

    Google Scholar 

  79. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002;9(2 Suppl):9–15.

    PubMed  Google Scholar 

  80. Krainick U, Astner A, Jonat W, et al. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer—final results of the German Neoadjuvant Aromasin Initiative (GENARI). San Antonio 2003 (abstr. 239).

    Google Scholar 

  81. Tubiana-Hulin M, Spyratos F, Becette V, et al. Phase II study of neoadjuvant exemestane in postmenopausal patients with operable breast cancer. San Antonio 2003 (abstr. 443).

    Google Scholar 

  82. Takei H, Suemasu K, Inoue K, et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat. 2008;107(1):87–94.

    Article  PubMed  CAS  Google Scholar 

  83. Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006;33:650–656. Review.

    Article  PubMed  CAS  Google Scholar 

  84. Smith I, Dowsett M. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. San Antonio 2003 (abstr. 1).

    Google Scholar 

  85. Gehan EA, Tefft MC. Will there be resistance to the RECIST (response evaluation criteria in solid tumors)? J Natl Cancer Inst 2000;92:179–181.

    Article  PubMed  CAS  Google Scholar 

  86. Wong ZW, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: an overlooked option? Oncology 2004;18;411–420.

    PubMed  Google Scholar 

  87. Tao Y, Klause A, Vickers A, et al. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 2005;95:91–95.

    Article  PubMed  CAS  Google Scholar 

  88. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB1- and/or ERB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  89. Miller WR, Anderson TJ, White S, et al. Growth factor signaling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Endocr Relat Cancer 2005;12 Suppl 1: S119–S123.

    Article  PubMed  CAS  Google Scholar 

  90. Miller WR, Larionov A, Renshaw L, et al. Aromatase inhibitors – gene discovery. J Steroid Biochem Mol Biol. 2007;106(1-5):130–142.

    Article  PubMed  CAS  Google Scholar 

  91. Miller WR, Larionov A, Anderson TJ, et al. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer 2008;112(3 Suppl):689--694.

    Google Scholar 

  92. Mackay A, Urruticoechea A, Dixon JM, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9(3):R37.

    Article  PubMed  Google Scholar 

  93. Cronin M, Sangli C, Liu ML, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53(6):1084–1091.

    Article  PubMed  CAS  Google Scholar 

  94. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817–2826.

    Article  PubMed  CAS  Google Scholar 

  95. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007;12(6):631–635.

    Article  PubMed  CAS  Google Scholar 

  96. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33): 5287–5312.

    Article  PubMed  CAS  Google Scholar 

  97. Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res 2004;10:391s–395s.

    Article  PubMed  CAS  Google Scholar 

  98. Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: a cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991;78:591–4.

    Article  PubMed  CAS  Google Scholar 

  99. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs. surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207–214.

    PubMed  CAS  Google Scholar 

  100. Tan SM, Cheung KL, Willsher PC, et al. Locally advanced primary breast cancer: medium-term results of a randomized trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001;37:2331–2338.

    Article  PubMed  CAS  Google Scholar 

  101. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003; 414–420.

    Google Scholar 

  102. Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39(3):309–316.

    Article  PubMed  CAS  Google Scholar 

  103. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66:191–199.

    Article  PubMed  CAS  Google Scholar 

  104. Miller WR, Dixon JM, Cameron DA, et al. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001;79:103–107.

    Article  PubMed  CAS  Google Scholar 

  105. Eiermann W, Paepke S, Appfelstaedt L, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12(11):1505–1506.

    Article  Google Scholar 

  106. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101–2109.

    Article  PubMed  CAS  Google Scholar 

  107. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB1- and/or ERB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808–3816.

    PubMed  CAS  Google Scholar 

  108. Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003;26(3):317–322.

    Article  PubMed  CAS  Google Scholar 

  109. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–3757.

    PubMed  CAS  Google Scholar 

  110. Nabholtz JM, Buzdar A, Pollak M, et al. Anatrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–3767.

    PubMed  CAS  Google Scholar 

  111. Dowsett M, Smith IE, Ebbs SR, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 2006;12(3 Pt 2):1024s–1030s.

    Article  PubMed  CAS  Google Scholar 

  112. Cataliotti L, Buzdar A, Noguchi S, et al. Efficacy of preoperative arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. Eur J Cancer 2004;2:46.

    Google Scholar 

  113. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14(9):1391–1398.

    Article  PubMed  CAS  Google Scholar 

  114. Tubiana-Hulin M, Becette V, Bieche I, et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res 2007;27(4C):2689–2696.

    PubMed  CAS  Google Scholar 

  115. Takei H, Suemasu K, Inoue K, et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat. 2008;107(1):87–94.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA

    Kelly K. Hunt

Authors
  1. Regina M. Fearmonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khandan Keyomarsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly K. Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly K. Hunt .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, U.S.A.

    Suzanne A. W. Fuqua

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fearmonti, R.M., Keyomarsi, K., Hunt, K.K. (2009). Biomarkers in Neoadjuvant Trials. In: Fuqua, S. (eds) Hormone Receptors in Breast Cancer. Cancer Treatment and Research, vol 147. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09463-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09463-2_8

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09462-5

  • Online ISBN: 978-0-387-09463-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation